UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Journal of clinical oncology, 2008-04, Vol.26 (12), p.2034-2039

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma

Clinical cancer research, 2008-02, Vol.14 (4), p.1105-1110

2008

Link zum Volltext

Verfügbarkeit prüfen

Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (13), p.3711-3718

2016

Link zum Volltext

Verfügbarkeit prüfen

A practical guide to the appropriate analysis of eGFR data over time: A simulation study

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Conditional power and information fraction calculations at an interim analysis for random coefficient models

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2024-03, Vol.23 (2), p.276-283

2024

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2015-09, Vol.21 (17), p.3862-3869

2015

Link zum Volltext

Verfügbarkeit prüfen

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Blood, 2020-11, Vol.136 (Supplement 1), p.11-12

2020

Link zum Volltext

Verfügbarkeit prüfen

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

Clinical cancer research, 2015-08, Vol.21 (16), p.3619-3630

2015

Link zum Volltext

Verfügbarkeit prüfen

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Clinical cancer research, 2017-05, Vol.23 (10), p.2451-2459

2017

Link zum Volltext

Verfügbarkeit prüfen

FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study

Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)

2022

Link zum Volltext

Verfügbarkeit prüfen

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2537-2537

2021

Link zum Volltext

Verfügbarkeit prüfen

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Blood, 2020-11, Vol.136 (Supplement 1), p.2-3

2020

Link zum Volltext

Verfügbarkeit prüfen

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8504-8504

2020

Link zum Volltext

Verfügbarkeit prüfen

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Blood, 2018-11, Vol.132 (Supplement 1), p.957-957

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Blood, 2017-12, Vol.130, p.2835-2835

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 960: Defined cell composition and precise control over JCAR017 dose enables identification of relationships between chimeric antigen receptor T cell product attributes, pharmacokinetics, and clinical endpoints in NHL

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.960-960

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2937: Localization of sipuleucel-T- expanded T cell clones into tumors of treated prostate cancer patients

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2937-2937

2014

Link zum Volltext

Verfügbarkeit prüfen

Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study)

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.122-122

2018

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e16071-e16071

2014

Link zum Volltext

Verfügbarkeit prüfen

Changes in circulating and intratumoral T cell clonotypes in sipuleucel-T-treated prostate cancer patients

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16008-e16008

2015

Link zum Volltext

Verfügbarkeit prüfen

PREDICT, a study evaluating baseline (BL) disease characteristics predictive of a positive imaging study for distant metastases in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary data

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16028-e16028

2015

Link zum Volltext

Verfügbarkeit prüfen

971 SAFETY AND CHANGES IN LABORATORY PARAMETERS ASSOCIATED WITH SIPULEUCEL-T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PHASE 2 PROACT STUDY

The Journal of urology, 2013-04, Vol.189 (4), p.e399-e399

2013

Link zum Volltext

Verfügbarkeit prüfen

MP87-15 RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T AND ANDROGEN DEPRIVATION THERAPY (STAND) IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: PRELIMINARY CLINICAL OUTCOMES

The Journal of urology, 2015-04, Vol.193 (4), p.e1089-e1090

2015

Link zum Volltext

Verfügbarkeit prüfen

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy

Cancer immunology research, 2015-09, Vol.3 (9), p.1063-1069

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(47)
Humans
(26)
Male
(20)
Aged
(15)
Female
(15)
Animals
(13)
Middle Aged
(13)
Biological And Medical Sciences
(11)
Adult
(10)
Aged, 80 And Over
(10)
Agriculture
(10)
Agriculture, Dairy & Animal Science
(10)
Ecology
(10)
Environmental Sciences & Ecology
(10)
Food Science & Technology
(10)
Oncology
(10)
Medical Sciences
(8)
Zoology
(8)
Cattle
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma

Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects

A practical guide to the appropriate analysis of eGFR data over time: A simulation study

Conditional power and information fraction calculations at an interim analysis for random coefficient models

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel)

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Abstract 960: Defined cell composition and precise control over JCAR017 dose enables identification of relationships between chimeric antigen receptor T cell product attributes, pharmacokinetics, and clinical endpoints in NHL

Abstract 2937: Localization of sipuleucel-T- expanded T cell clones into tumors of treated prostate cancer patients

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study)

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)

Changes in circulating and intratumoral T cell clonotypes in sipuleucel-T-treated prostate cancer patients

PREDICT, a study evaluating baseline (BL) disease characteristics predictive of a positive imaging study for distant metastases in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary data

971 SAFETY AND CHANGES IN LABORATORY PARAMETERS ASSOCIATED WITH SIPULEUCEL-T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PHASE 2 PROACT STUDY

MP87-15 RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T AND ANDROGEN DEPRIVATION THERAPY (STAND) IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: PRELIMINARY CLINICAL OUTCOMES

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy

Suchergebnisse filtern